Valerie Jansen

April 20, 2017

Study examines new breast cancer drug combination

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy.

By VUMC News and Communications
October 1, 2015

VICC investigators land Komen breast cancer grants

Two Vanderbilt-Ingram Cancer Center (VICC) investigators — Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of VICC, and Valerie Jansen, M.D., Ph.D., medical oncology fellow — have received new cancer research grants awarded by Susan G. Komen, the world’s largest nonprofit funder of breast cancer research.

By VUMC News and Communications